IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of HLA-A*02:01 allele status or line of therapy OptimUM-01 data demonstrates encouraging clinical...
Covered in this story
What has happened since
- Ideaya Biosciences Inc is up 6.8% since this was published, 3 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Ideaya Biosciences Inc
- Stifel: $34.3 → $48 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $IDYA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ideaya Biosciences Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.